The U.S. Food and Drug Administration announced that eftilagimod alfa, Immutep’s lead oncology asset, has received orphan drug designation for the treatment of soft tissue sarcoma. The designation grants the company fee waivers, potential tax credits, and a seven‑year period of market exclusivity if the drug is approved, thereby improving the commercial prospects of the program.
Eftilagimod alfa’s designation is backed by encouraging data from the Phase II EFTISARC‑NEO trial, in which 38 evaluable patients achieved a median tumor hyalinization/fibrosis rate of 51.5%. This figure exceeds the target of 35% and surpasses historical benchmarks of roughly 15%, underscoring the drug’s potential efficacy in a rare and difficult‑to‑treat cancer.
The announcement comes amid a broader review of Immutep’s pipeline following the discontinuation of its Phase III TACTI‑004 trial for non‑small cell lung cancer. CEO Marc Voigt said, "We are pleased that the FDA has recognised the potential of efti for patients with soft tissue sarcoma, a rare and difficult to treat cancer." He added, "The FDA's designation, based on very encouraging data from the EFTISARC‑NEO trial, provides us with a potential direct step forward into a late‑stage study in the neoadjuvant setting for STS."
The designation was well received by investors, reflecting confidence in the drug’s potential and the company’s ability to navigate setbacks in other indications. Analysts noted that the milestone could broaden Immutep’s commercial portfolio and enhance its attractiveness to partners and investors.
The orphan drug status positions eftilagimod alfa as a promising candidate for future late‑stage development in soft tissue sarcoma, potentially opening a new therapeutic avenue for the company’s pipeline and providing a strategic counterbalance to recent challenges in other programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.